(Q33596439)

28 July 2017

Statistical analysis of cost-effectiveness data from randomized clinical trials (English)

1 reference

cost-effectiveness analysis

28 July 2017

0 references

1 reference

Andrew R Willan

1

1 reference

28 July 2017

1 June 2006

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

28 July 2017

1 reference

28 July 2017

6

1 reference

28 July 2017

3

1 reference

28 July 2017

337-346

1 reference

Using inverse-weighting in cost-effectiveness analysis with censored data

28 July 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Estimating country-specific cost-effectiveness from multinational clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Assessing the appropriateness of combining economic data from multinational clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Using multilevel models for assessing the variability of multinational resource use and cost data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Cost-effectiveness analysis for multinational clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

How should cost data in pragmatic randomised trials be analysed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Parametric modelling of cost data in medical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Parametric modelling of cost data: some simulation evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

The importance of the normality assumption in large public health data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Incremental net benefit in randomized clinical trials with quality-adjusted survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Estimating medical costs from incomplete follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Incremental net benefit in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Linear regression analysis of censored medical costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

On estimating medical cost and incremental cost-effectiveness ratios with censored data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Regression methods for cost-effectiveness analysis with censored data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

The value of information and optimal clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.6.3.337

21 January 2018

Identifiers

DOI

10.1586/14737167.6.3.337

1 reference

28 July 2017

1 reference

PubMed ID

20528526